Some people cannot collect a prescription because they can’t afford a long journey. Others cannot take time off work and face loss of wages. In extreme situations, there is simply no doctor to see, no healthcare clinic to visit, or no available medicine in the pharmacy.
The unfortunate reality is that only a fraction of patients with these diseases receive treatment today. We need to close that gap and help people gain affordable access to the medicines we manufacture and the care they need.
The barriers are complex and differ from country to country, but we know from experience that change is possible.
Our ambition is to offer access to our available medicines to the greatest number of people living with diabetes, rare blood diseases and rare endocrine disorders, while addressing varying levels of affordability.
We place extra focus on people living with diabetes in low-and middle-income countries. We have established affordability and access programmes to help patients in need in over two-thirds of the countries in which we operate.
Read on to learn more about our commitment to affordable treatment and access to diabetes care.
In some countries, people living with haemophilia may be unable to store their haemophilia medication at home. During the COVID-19 crisis, many patients were then unable to visit hospitals to seek treatment.
When people living with a rare blood disease face these situations, we work with local health authorities and partner organisations to provide financial support for medicine and treatment home delivery.
To ensure clear and transparent relationships, our initiatives are designed in dialogue with policy makers, for support services related to patient training, delivery and medicine storage.